Hedge fund manager Stanley Druckenmiller increased his Natera position to 18% of his $3.4 billion U.S.-listed stock holdings.
Stanley Druckenmiller’s family office raised its stake in genetic testing firm Natera (NTRA) to 18% of its $3.4 billion U.S.-listed portfolio. The move highlights confidence in Natera’s growth amid rising demand for advanced diagnostics in prenatal and cancer care.
Natera specializes in cell-free DNA testing, offering non-invasive solutions for fetal health and cancer monitoring. The company holds patent protections and leads in a rapidly expanding market, recently expanding into organ donor testing.
The 13-F filing reveals Druckenmiller’s concentrated bet, though market reaction to the disclosure remains unclear.